GlassScriptPhysician profile
Melissa A Gaines
NPI 1376557264
$16,010.33
in general payments reported to CMS, 2019-2025
23 companies · $6,531 in 2025
The $6,531 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.14 · 2020: $15.45 · 2023: $541 · 2024: $8,909 · 2025: $6,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,918 · Travel and Lodging: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,650.00 |
| Food and Beverage | $2,917.64 |
| Travel and Lodging | $2,413.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13,786.33 | 2024-2025 | Kisunla, Amyvid, Zepbound |
| Astrazeneca Pharmaceuticals LP | $527.76 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Eisai INC. | $357.11 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $282.05 | 2023-2024 | Ingrezza, Ongentys |
| Abbott Laboratories | $217.02 | 2023-2025 | Freestyle Libre |
| Novo Nordisk INC | $152.65 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $88.24 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.05 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $75.54 | 2024-2025 | |
| Mylan Specialty L.P. | $72.42 | 2023-2024 | Yupelri |
| Dexcom, INC. | $48.15 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $46.01 | 2023-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $44.21 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $40.07 | 2024-2025 | Belbuca |
| Globus Medical, INC. | $37.03 | 2025 | Senza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.87 | 2023-2025 | Eliquis |
| Exact Sciences Corporation | $19.98 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.49 | 2025 | Xifaxan |
| Viatris Specialty LLC | $16.45 | 2025 | Yupelri |
| Medtronic, INC. | $15.60 | 2024 | Kyphon Express II Kyphopak Tray |
| Merck Sharp & Dohme LLC | $15.36 | 2024 | Delstrigo, Dificid, Pifeltro |
| Allergan, INC. | $14.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.